Brentuximab vedotin (BV), an antibody-drug conjugate that targets CD30, induces high response rates in CD30+ lymphoid malignancies. considered to be 5106 CD34+ cells/kg 2,3, 5 to 40% of patients fail to gather at the least 2106 Compact disc34+ cells per kilogram 4-6. Particular antineoplastic agents have already been connected with poor mobilization prices, including lenalidomide… Continue reading Brentuximab vedotin (BV), an antibody-drug conjugate that targets CD30, induces high